Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18778554 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18419845 | SMALL PEPTIDE COMPOSITIONS AND USES THEREOF | January 2024 | June 2025 | Allow | 17 | 0 | 1 | Yes | No |
| 18464046 | PTH Prodrugs | September 2023 | September 2024 | Allow | 12 | 1 | 0 | No | No |
| 18365328 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF | August 2023 | March 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18345226 | DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATION | June 2023 | May 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18212244 | Treatment of Muscular Dystrophies | June 2023 | February 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18331904 | LINKED AND OTHER pH-TRIGGERED COMPOUNDS | June 2023 | January 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18330032 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18099378 | CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTION | January 2023 | June 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18096941 | USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTH | January 2023 | March 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18093509 | DISULFIDE BOND CONTAINING COMPOUNDS AND USES THEREOF | January 2023 | April 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18053693 | PTH Prodrugs | November 2022 | July 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 18047150 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTION | October 2022 | October 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17935096 | CONTROLLABLE SELF-ANNEALING MICROGEL PARTICLES FOR BIOMEDICAL APPLICATIONS | September 2022 | November 2023 | Abandon | 13 | 0 | 1 | No | No |
| 17778823 | MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2 | May 2022 | May 2024 | Allow | 24 | 2 | 1 | No | No |
| 17724900 | SMALL PEPTIDE COMPOSITIONS AND USES THEREOF | April 2022 | October 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17687755 | MATING FACTOR ALPHA PRO-PEPTIDE VARIANTS | March 2022 | February 2024 | Allow | 24 | 0 | 1 | Yes | No |
| 17680070 | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME | February 2022 | January 2025 | Abandon | 35 | 2 | 1 | Yes | No |
| 17586737 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | January 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17552748 | Pharmaceutical composition with improved stability | December 2021 | November 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17532484 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF | November 2021 | November 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17612993 | VARIANT CD58 DOMAINS AND USES THEREOF | November 2021 | March 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17455649 | GDF15 FUSION PROTEINS AND USES THEREOF | November 2021 | April 2025 | Abandon | 41 | 4 | 1 | No | Yes |
| 17525531 | VARIANT OF A BPIFB4 PROTEIN | November 2021 | September 2023 | Allow | 23 | 0 | 1 | Yes | No |
| 17608487 | INTERFERON REGULATORY FACTOR 5 INHIBITORS AND USES THEREOF | November 2021 | March 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17516977 | NOVEL DRUG DELIVERY CONJUGATED MOIETY FOR ORAL ADMINISTRATION OF DRUG UNSUITABLE FOR ORAL ADMINISTRATION AND PREPARATION METHOD THEREOF | November 2021 | January 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17504072 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | October 2021 | February 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17503356 | Multivalent Plant Immune Fusion Protein, Production Method Thereof and Its Use | October 2021 | April 2023 | Allow | 18 | 1 | 1 | No | No |
| 17488137 | PTH Prodrugs | September 2021 | November 2022 | Abandon | 14 | 2 | 1 | No | No |
| 17479705 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | September 2021 | November 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17434538 | POLYPEPTIDE HAVING ANTIBACTERIAL ACTIVITY, COMPOSITION FOR PREVENTING OR TREATING SEPSIS COMPRISING SAME, AND ANTIBACTERIAL COMPOSITION | August 2021 | April 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17432077 | PEPTIDE-FUNCTIONALIZED BIODEGRADABLE POLYMERS FOR EFFICIENT DELIVERY OF VARIOUS RNAS | August 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17429153 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17393529 | BIOINSPIRED HIGHLY THERMO-SUSTAINABLE PACKINGS WITH USES THEREOF | August 2021 | February 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17389761 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | July 2021 | May 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17423341 | PROTEINS AND FLUOROPHORE-CONTAINING COMPOUNDS SELECTIVE FOR NaV1.7 | July 2021 | September 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17374437 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | July 2021 | April 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17363698 | SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITY | June 2021 | January 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17358035 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | June 2021 | May 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17358142 | FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF | June 2021 | January 2024 | Allow | 31 | 4 | 1 | No | No |
| 17349669 | USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTH | June 2021 | January 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17332338 | COMPOSITIONS FOR INHIBITING KRAS SIGNALING AND METHODS OF MAKING AND USING SAME | May 2021 | May 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17326247 | METHODS AND COMPOSITIONS FOR PROTEIN SEQUENCING | May 2021 | April 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17291616 | COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, COMPRISING AEG-1 S298D AS ACTIVE INGREDIENT | May 2021 | March 2025 | Allow | 47 | 2 | 0 | No | No |
| 17306623 | DESIGNED, ENZYMATIC BIOCIDE FOR REMOVAL OF FOODBORNE MICROBIAL CONTAMINATION | May 2021 | May 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17246307 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTION | April 2021 | July 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17240351 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME | April 2021 | July 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17287390 | PHARMACEUTICAL COMPOSITION COMPRISING TEICOPLANIN | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17285811 | PYRROLOBENZODIAZEPINE CONJUGATES | April 2021 | September 2023 | Abandon | 29 | 3 | 1 | No | No |
| 17224505 | TARGETED NON-INVASIVE IMAGING PROBES OF EGFR EXPRESSING CELLS | April 2021 | February 2023 | Allow | 22 | 0 | 0 | Yes | No |
| 17282831 | HYPOGLYCEMIC PHARMACEUTICAL COMPOSITION | April 2021 | May 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17250969 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ULCER OR FISTULA IN INTESTINAL TRACT | April 2021 | June 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17281870 | ENGINEERED ACTIVE SINGLE-POLYPEPTIDE CHAIN INSULIN ANALOGS | March 2021 | April 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17280738 | NOVEL HYDROGEL CONJUGATES | March 2021 | June 2025 | Abandon | 50 | 2 | 1 | Yes | No |
| 17214530 | CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN | March 2021 | February 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17279772 | CD40L ANTAGONIST AND USES THEREOF | March 2021 | April 2024 | Abandon | 36 | 0 | 1 | Yes | No |
| 17279961 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION | March 2021 | November 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17279174 | GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOF | March 2021 | February 2025 | Abandon | 47 | 2 | 1 | Yes | No |
| 17204627 | DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATION | March 2021 | March 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17185788 | EXPRESSION AND PURIFICATION OF CAS ENZYMES | February 2021 | November 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17172533 | Method for accelerated healing of burn wounds | February 2021 | March 2024 | Abandon | 37 | 2 | 0 | No | Yes |
| 17152239 | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME | January 2021 | July 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17150426 | EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME | January 2021 | April 2024 | Allow | 39 | 3 | 1 | No | No |
| 17144158 | CONTROLLABLE SELF-ANNEALING MICROGEL PARTICLES FOR BIOMEDICAL APPLICATIONS | January 2021 | June 2022 | Allow | 17 | 0 | 0 | Yes | No |
| 17142276 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | January 2021 | January 2022 | Abandon | 12 | 2 | 1 | No | No |
| 17137188 | PD-L 1-BINDING POLYPEPTIDE AND USE THEREOF | December 2020 | November 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17134185 | METHOD OF PRODUCING IMIDAZOLE DIPEPTIDES | December 2020 | November 2024 | Abandon | 46 | 3 | 1 | Yes | No |
| 17254391 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | December 2020 | May 2024 | Abandon | 40 | 1 | 1 | Yes | No |
| 17056545 | Translocation into Eukaryotic Cells | November 2020 | February 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17055809 | MATRIX METALLOPROTEINASE-1 ANTISENSE OLIGONUCLEOTIDES | November 2020 | March 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17091500 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | November 2020 | March 2025 | Allow | 52 | 2 | 1 | No | No |
| 17084082 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | October 2020 | April 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17078978 | Bi-Specific Fusion Proteins | October 2020 | January 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17048988 | A METHOD FOR PRODUCTION OF HIGH PURITY ICATIBANT | October 2020 | August 2022 | Abandon | 22 | 2 | 1 | No | No |
| 17045058 | FACTOR B AND C2 PROTEIN POINT MUTANTS, A METHOD FOR ENHANCING THE ACTIVITY OF ANTI-CANCER ANTIBODIES, THE PHARMACEUTICAL COMPOSITION AND THE USE OF MUTANTS | October 2020 | March 2022 | Allow | 18 | 2 | 0 | Yes | No |
| 17036396 | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME | September 2020 | April 2022 | Abandon | 18 | 0 | 1 | No | No |
| 17028662 | Peptides Having Anti-Inflammatory Properties | September 2020 | October 2024 | Abandon | 48 | 4 | 1 | No | No |
| 16982638 | CYCLIC TETRAPEPTIDE ANALOGS | September 2020 | March 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 16993702 | ZINC ACTIVATED THYMULIN AND METHODS OF PREPARATION AND ADMINISTRATION | August 2020 | January 2024 | Abandon | 41 | 3 | 1 | Yes | No |
| 16991803 | Process for the Preparation of Insulin-Zinc Complexes | August 2020 | June 2024 | Abandon | 46 | 3 | 1 | No | No |
| 16988302 | PTH PRODRUGS | August 2020 | November 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16988386 | PTH PRODRUGS | August 2020 | December 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16932113 | Method of Treating Parkinson's Disease | July 2020 | October 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16927590 | MODULAR DIMERIZATION THERMOSWITCHES AND RELATED MONOMERS, DIMERS, CONSTRUCTS, DIMERIC COMPLEXES, VECTORS, CELLS, SURFACES, DEVICES COMPOSITIONS, METHODS AND SYSTEMS | July 2020 | October 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16901101 | INHIBITION-RESISTANT POLYMERASES | June 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | Yes |
| 16898378 | THERAPEUTIC COMPOSITION FOR USE IN THE TREATMENT OF COVID-19 AND OTHER CYTOKINE STORM ASSOCIATED DISORDERS | June 2020 | October 2023 | Allow | 40 | 5 | 1 | Yes | Yes |
| 16770299 | Methods For Treatment of Neuropathic Pain | June 2020 | April 2025 | Abandon | 59 | 3 | 1 | No | Yes |
| 16770358 | Treatment of Muscular Dystrophies | June 2020 | March 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16768281 | METHODS FOR REDUCING RISK OF ONSET OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATION | May 2020 | August 2023 | Allow | 39 | 2 | 1 | No | No |
| 16879534 | EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE | May 2020 | May 2024 | Abandon | 48 | 3 | 1 | Yes | No |
| 16872826 | METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHOGONAL PYLRS SYNTHASE | May 2020 | February 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 16762391 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | May 2020 | June 2024 | Abandon | 49 | 3 | 1 | No | Yes |
| 16842408 | Drug Delivery Enhancement Agents | April 2020 | June 2022 | Abandon | 27 | 2 | 1 | No | No |
| 16651921 | LONG ACTING PROTEIN COMPLEX HAVING AN ENHANCED EFFICIENCY | March 2020 | February 2024 | Abandon | 47 | 6 | 1 | Yes | No |
| 16651813 | POLYION COMPLEX POLYPEPTIDE HYDROGELS AND USES THEREOF | March 2020 | October 2024 | Allow | 54 | 5 | 1 | Yes | No |
| 16650719 | CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTION | March 2020 | May 2023 | Abandon | 38 | 4 | 1 | No | No |
| 16642233 | PHARMACEUTICAL COMPOSITION FOR TREATING KELOID AND USES THEREOF | February 2020 | May 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16777125 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME | January 2020 | September 2023 | Abandon | 43 | 3 | 1 | Yes | No |
| 16634099 | MALARIA VACCINE | January 2020 | September 2024 | Abandon | 56 | 4 | 1 | Yes | No |
| 16633610 | SUPERACTIVE MUTANT THYMIDINE KINASE FOR USE IN CANCER THERAPY | January 2020 | July 2022 | Abandon | 30 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BEANE, RANDALL L.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BEANE, RANDALL L works in Art Unit 1654 and has examined 295 patent applications in our dataset. With an allowance rate of 36.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner BEANE, RANDALL L's allowance rate of 36.9% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BEANE, RANDALL L receive 2.06 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BEANE, RANDALL L is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.7% benefit to allowance rate for applications examined by BEANE, RANDALL L. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.4% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.6% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 70.7% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.